Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

Case Western Reserve researchers found semaglutide users had significantly lower Alzheimer's-related dementia risk compared ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from semaglutide ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

GLP-1 drugs may be hailed as a medical breakthrough in obesity care, but Indian experts warn they are no cosmetic quick-fix.

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

The typical symptoms you have for stomach cancer, I had none of them, just the reflux,” Chloe Stirling shared of her shock ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone ...